VORINOSTAT

VORINOSTAT

Vorinostat, is a high-quality raw ingredient produced under strict GMP (Good Manufacturing Practice) conditions. Vorinostat is a potent and selective histone deacetylase (HDAC) inhibitor widely recognised for its therapeutic potential in the treatment of various cancers. As a pharmaceutical-grade raw material, Vorinostat is designed to meet the needs of research, development, and manufacturing of finished dosage forms in the oncology space.

REQUEST A QUOTE
Product successfully added to Quote Basket!
View Quote Basket

Selective HDAC Inhibition: Vorinostat targets and inhibits histone deacetylases (HDACs), leading to tumor-suppressor gene activation and apoptosis in cancer cells.

Proven Efficacy in Oncology: Demonstrated clinical success in treating cutaneous T-cell lymphoma (CTCL), with ongoing research into its use for other malignancies.

GMP-Grade Raw Material: Manufactured under strict GMP conditions, ensuring consistency, purity, and regulatory compliance for pharmaceutical and biotech applications.

Mechanism of Action

Vorinostat functions by inhibiting the activity of histone deacetylases (HDACs), enzymes that play a key role in the regulation of gene expression. HDACs remove acetyl groups from histone proteins, which leads to chromatin condensation and the repression of gene transcription. By inhibiting HDACs, Vorinostat causes hyperacetylation of histones, leading to the activation of tumor-suppressor genes and the induction of apoptosis (programmed cell death) in cancer cells. This effect not only disrupts cancer cell proliferation but also promotes differentiation and cell cycle arrest, particularly in hematological malignancies such as cutaneous T-cell lymphoma (CTCL).

Additionally, Vorinostat has been shown to modulate various signalling pathways involved in cancer progression, including the p53 pathway and the regulation of proteins like Bcl-2. Its ability to alter gene expression at the chromatin level offers significant promise for the treatment of a wide range of cancers, both solid and hematologic.

About MedicaPharma

MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.

What is Vorinostat

Vorinostat, marketed under the brand name Zolinza, is an innovative medication primarily used in the treatment of cutaneous T-cell lymphoma (CTCL), a type of cancer that affects the skin.

Why Choose MedicaPharma

We are committed to supplying high-quality GMP products with logistics according to GDP regulations.

Table of Contents

Benefits and Advantages

Vorinostat offers multiple advantages for pharmaceutical companies and researchers focused on oncology therapeutics:

  • Targeted Cancer Therapy: By modulating the epigenetic landscape, Vorinostat selectively affects cancer cells while sparing normal cells, leading to reduced off-target effects and improving therapeutic outcomes.
  • Proven Clinical Efficacy: Vorinostat has demonstrated clinical success in the treatment of conditions such as cutaneous T-cell lymphoma (CTCL) and is under investigation for its potential in treating other malignancies, including solid tumors.
  • Versatile Research Tool: As an HDAC inhibitor, Vorinostat can be used in research to investigate epigenetic modifications and their role in cancer progression, drug resistance, and tumor microenvironment changes.
  • Regulatory Compliance: MedicaPharma’s Vorinostat is manufactured in accordance with the highest industry standards, ensuring a reliable, compliant raw material for pharmaceutical manufacturers worldwide.

 

Additionally, Vorinostat can be incorporated into combination therapies with other anticancer agents to enhance treatment efficacy and overcome resistance mechanisms that often develop during cancer treatment.

Side Effects and Risks

While Vorinostat is a promising therapeutic agent, like any pharmacological compound, it comes with a profile of potential side effects and risks. The most commonly reported adverse effects in clinical trials include gastrointestinal symptoms such as nausea, diarrhoea, and vomiting, which can impact patient quality of life. Hematologic side effects, such as thrombocytopenia and anaemia, are also frequently observed, especially at higher doses.

Other side effects may include fatigue, anorexia, and electrolyte imbalances. Prolonged use of Vorinostat may lead to liver toxicity, with elevated liver enzymes being a concern. Careful monitoring of liver function is recommended during treatment, and dose adjustments may be necessary in patients with pre-existing liver conditions.

Given the potential for severe side effects, Vorinostat should only be administered under the supervision of qualified healthcare professionals, particularly in the context of clinical trials or in combination with other chemotherapeutic agents.

Conclusion

Vorinostat is a potent and selective HDAC inhibitor with significant promise in the treatment of various cancers, particularly hematologic malignancies. As a raw GMP ingredient, it provides pharmaceutical manufacturers and research institutions with a high-quality, reliable product that complies with the strictest regulatory standards.

MedicaPharma ensures that its Vorinostat is produced with the highest level of care, providing the pharmaceutical industry with a trustworthy and effective ingredient for use in cancer therapies.

While Vorinostat offers several benefits, including targeted action, proven efficacy, and the ability to be used in combination therapies, it is essential to monitor potential side effects and risks associated with its use. Ongoing clinical investigations and further refinement of treatment regimens will continue to expand its therapeutic potential and optimize its safety profile for patients. For industry professionals seeking a reliable raw material for cutting-edge oncology therapeutics, MedicaPharma’s Vorinostat stands out as a premier choice.

Download GMP-Certified API Product List

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations. Click here to download our full API product list.
Download
New !

Recommended articles